reach semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or Semaglutide Houston | Weight Loss

Cumulative incidence estimates are based on time from randomization to first EAC-confirmed MACE with non-CV death modeled as competing risk using the Aalen-Johansen estimator

Semaglutides ability to promote significant weight loss can help alleviate the strain that excess weight places on the heart and blood vessels

This is not a failure of willpower but rather reflects the medication's role in appetite regulation and the body's metabolic adaptation

However, like other GLP-1 receptor agonists, it may not be suitable for individuals with a history of thyroid cancer, certain endocrine disorders, or severe gastrointestinal conditions